Miriam Rodi

Dr. Miriam Rodi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JIJuliana Inoue
Juliana Inoue
MRMiriam Rodi
Miriam Rodi
TBTowanou Emmanuel Francis Bohissou
Towanou Emmanuel Francis Bohissou
LCLais Pessanha De Carvalho
Lais Pessanha De Carvalho
KLKatharina Lohse
Katharina Lohse
JHJana Held
Jana Held
The emergence of chloroquine-resistant Plasmodium falciparum in the 1950s posed a global threat to malaria control. Ceasing chloroquine use restored chloroquine-sensitive strains in many African countries. To assess whether chloroquine sensitivity re-emerged in Lambaréné, Gabon, we compiled published and new data on P. falciparum ex vivo chloroquine susceptibility, quantified as half-maximal inhibitory concentration (IC50), from four time points between 2004 and 2024. We then assessed the prevalence of pfcrt and pfmdr1 polymorphisms associated with chloroquine resistance via real-time PCR and Sanger sequencing, respectively, at six different time points between 2009 and 2024. Ex vivo chloroquine susceptibility data revealed a stepwise decrease in the median chloroquine IC50 from 2004 (113.8 nM; IQR: 79.6–163.5 nM, n = 42), 2009 (46.7 nM; IQR: 27.4–76.9 nM, n = 26), and 2017–2018 (15.6 nM; IQR: 6.1–40.9 nM, n = 46) to 2024 (2.1 nM; IQR: 0.8–6.1 nM, n = 39). The chloroquine-sensitive pfcrt haplotype CVMNK increased from 3.6% (1/28) in 2009 to 98.2% (56/57) in 2024, as well as the wild-type pfmdr1 N86 (23.1% (6/16), 2009; 100% (19/19), 2024). Paired molecular and ex vivo analyses revealed an association between IC50 values and CVMNK pfcrt and pfmdr1 N86. Our data provide evidence for the reestablishment of chloroquine-sensitive P. falciparum in Lambaréné, Gabon.

28 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MIMoses Ikegbunam
Moses Ikegbunam
VTVasileios Tzirtziganis
Vasileios Tzirtziganis
MRMiriam Rodi
Miriam Rodi
LALinda Anagua
Linda Anagua
LCLais Pessanha De Carvalho
Lais Pessanha De Carvalho
JHJana Held
Jana Held
Artemisinin-based combination therapies (ACTs) are currently the first-line treatment for uncomplicated malaria. However, ACTs are being threatened by the emergence of Plasmodium falciparum strains resistant to artemisinins as well as their partner drugs. Periodical surveillance of drug efficacy and molecular markers associated with resistance is required to monitor this. Resistance to piperaquine (PPQ), the partner drug in the ACT dihydroartemisinin-piperaquine, is spreading in Asia, and mutations associated with PPQ resistance have been reported in some African countries. In Nigeria, this has never been reported. This study aimed to assess markers of PPQ resistance—specifically, the T93S, H97Y, and F145I SNPs in exons 2 and 3 of the P. falciparum chloroquine resistance transporter (pfcrt) gene—and to examine amplification of the plasmepsin 2 and 3 genes (pfpm2/3) in 268 patient samples collected from Nnewi, Southeastern Nigeria, in 2019. SNPs were identified using PCR followed by sequencing, while pfpm2/3 copy number was determined by qPCR. No pfcrt SNPs of interest were detected, and no increase in copy number for pfpm2 or pfpm3 was observed in any sample. The absence of these PPQ resistance markers suggests that PPQ remains an effective partner drug in ACTs in this region. However, continuous monitoring of circulating P. falciparum parasites in Nigeria is crucial to promptly detect and respond to potential resistance development.